Overview

Single and Multiple Ascending Dose Study of KN-002

Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 2 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in subjects with stable, mild asthma
Phase:
Phase 1
Details
Lead Sponsor:
Kinaset Therapeutics Inc